 Adds RezurockTM belumosudil an FDA-approved, first-in-class treatment for adult and pediatric patients 12 years and older with chronic graft-versus-host disease cGVHD after failure of at least two prior lines of systemic therapy PARIS, FRANCE and NEW YORK, NY ACCESSWIRE September 8, 2021 Sanofi has entered into a definitive merger agreement with Kadmon Holdings, Inc. NASDAQ:KDMN a biopharmaceutical company that discovers, develops, and markets transformative therapies for disease areas of significant unmet medical needs. The acquisition supports Sanofis strategy to continue to grow its General Medicines core assets and will immediately add RezurockTM belumosudil to its transplant portfolio. 